MULTABODY
Live / Applied — First extension granted (statement of use) (as of 01 Dec 2025)
What this means for you
Not registered yet, but its 12 Jul 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98081053
- Mark type
- Stylized text
- Filed
- 12 Jul 2023
- Published for opposition
- 08 Apr 2025
- Attorney of record
- Tom M. Monagan
Goods and services
- Class 001 — Chemicals: Chemical, biochemical, biological, and biotechnological, preparations, namely, antibodies, bi- and multispecific antibodies as well as fragments, monovalent antibodies, derivatives of conjugates of any of these for in vitro and in vivo scientific and industrial research and development with regard to diseases; biochemicals, namely, monoclonal antibodies for in vivo or in vitro scientific research and development regarding cancer, AIDS (acquired immune deficiency syndrome), and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases
- Class 005 — Pharmaceuticals: Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations based on antibodies, bi and multispecific antibodies as well as fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases; pharmaceutical preparations based on human monoclonal antibodies for the treatment of cancer, AIDS (acquired immune deficiency syndrome) and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases
- Class 042 — Scientific and technological services: Medical, scientific and biological research; research in antibodies, bi and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these and development services of new pharmaceutical products based on antibodies, bi and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these; chemical analysis; development of pharmaceutical preparations and medicines containing antibodies, bi- and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these; medical and scientific research, namely, biological scientific research into human monoclonal antibodies and development of pharmaceutical products based on human monoclonal antibodies for the treatment of cancer, AIDS (acquired immune deficiency syndrome) and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases
- Class 045 — Legal and security services: Licensing of intellectual property in the field of medicine
Owner
- Radiant Biotherapeutics, Toronto, ON, CA
- Radiant Biotherapeutics, Toronto, ON, CA
Prosecution history
- 02 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Dec 2025 — SOU EXTENSION 1 GRANTED
- 01 Dec 2025 — SOU EXTENSION 1 FILED
- 01 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 28 Nov 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 28 Nov 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 28 Nov 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 28 Nov 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 28 Nov 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 03 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Apr 2025 — PUBLISHED FOR OPPOSITION
- 02 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 13 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Oct 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED